A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Terminated · Phase 2, Phase 3 · NCT04517253
Conditions: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
At a glance
- Research payments reported, 2025
- $8,100
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Baricitinib (drug)
- Dates
- Started 2020-10-27; completion 2024-11-28
- Results posted
- Yes
The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières Syndrome (AGS).
From ClinicalTrials.gov, last updated 2025-07-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $8,100 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.